Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-270386
Filing Date
2026-06-15
Accepted
2026-06-15 09:16:50
Documents
79
Period of Report
2026-04-30

Document Format Files

Seq Description Document Type Size
1 10-Q engn-20260430.htm   iXBRL 10-Q 2492669
2 EX-10.2 engn-ex10_2.htm EX-10.2 131072
3 EX-10.3 engn-ex10_3.htm EX-10.3 156313
4 EX-31.1 engn-ex31_1.htm EX-31.1 23166
5 EX-31.2 engn-ex31_2.htm EX-31.2 22358
6 EX-32.1 engn-ex32_1.htm EX-32.1 11924
7 EX-32.2 engn-ex32_2.htm EX-32.2 11914
  Complete submission text file 0001193125-26-270386.txt   11789244

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20260430.xsd EX-101.SCH 1808708
83 EXTRACTED XBRL INSTANCE DOCUMENT engn-20260430_htm.xml XML 2220722
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT Quebec, Canada
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT Quebec, Canada (514) 332-4888
enGene Therapeutics Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41854 | Film No.: 261089205
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)